Basic Science |
BS |
Omics |
[14, 52, 17, 18, 29, 35, 48, 19, 13, 31] |
✓ |
|
✓ |
Biomarker development |
[32, 35, 29] |
✓ |
|
|
Subcohort identification |
[13, 25, 35, 21, 27] |
✓ |
|
✓ |
Epidemiology |
[48, 33, 21, 24, 26, 20, 22, 29, 35, 23, 30, 19, 34] |
✓ |
✓ |
✓ |
Translational science |
T |
Increased research projects |
[14, 33, 21, 23, 17, 30, 19, 22, 29, 18, 34] |
✓ |
✓ |
✓ |
Randomised controlled trials |
[48, 33, 34, 32, 22, 23, 21, 27, 29] |
✓ |
✓ |
|
Biospecimen contribution to studies |
[31, 17, 19, 27, 18, 32, 29, 25, 35, 24, 48, 49, 13, 14] |
✓ |
|
✓ |
Clinical observation |
CO |
Diagnosis/survival rate |
[28, 29, 25, 20, 19, 50, 51] |
✓ |
✓ |
|
Natural history of disease |
[31, 24, 27, 30, 23, 21, 28, 22, 29] |
✓ |
✓ |
|
Clinical treatment |
CT |
Diagnostics |
[17, 18, 33] |
✓ |
✓ |
|
Guidelines for treatment |
[32, 20, 21, 33, 25, 29] |
✓ |
✓ |
|
Treatment evaluation |
[26, 27, 30, 31, 20, 28, 33, 29, 25, 24] |
✓ |
✓ |
|
Facilitators |
F |
Benefits to stakeholders |
[23, 17, 18, 14, 32, 19, 22, 13] |
✓ |
✓ |
✓ |
Collaborations |
[24, 48, 20, 13, 26, 22, 17, 18, 32, 29, 33, 35, 30, 25, 49, 19, 21, 27] |
✓ |
✓ |
✓ |
Engagement |
[29, 30, 32, 34, 35] |
✓ |
✓ |
✓ |
Recruitment |
[34] |
✓ |
|
|
Pro-active marketing |
[14] |
|
|
✓ |
Barriers |
B |
Challenges |
[13, 17, 19, 21, 23–26, 29, 31, 33, 34] |
✓ |
✓ |
✓ |